Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults
Condition: Typhoid Fever Interventions: Biological: TYP04A Low Dose without adjuvant investigational vaccine; Biological: TYP04B Full Dose without adjuvant investigational vaccine; Biological: TYP03A Low Dose adjuvanted investigational vaccine; Biological: TYP03B Full Dose adjuvanted investigational vaccine; Biological: Sa nofi Pasteur's Typhoid Vi polysaccharide vaccine; Biological: GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine Sponsors: GlaxoSmithKline; Biological E. Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2022 Category: Research Source Type: clinical trials